Evidências sobre a eficácia e segurança do canabidiol no tratamento da epilepsia infantil fármaco-resistente
Conteúdo do artigo principal
Resumo
Introdução: A epilepsia é uma doença com múltiplas repercussões para o indivíduo, sistemas de saúde e sociedade. Casos de epilepsia refratária ou fármaco-resistente, como West, síndrome de Lennox-Gastaut e a síndrome de Dravet são frequentemente observados em crianças, afetando seu desenvolvimento e qualidade de vida. Objetivo: Identificar, na literatura científica internacional, as evidências clínicas sobre o uso do canabidiol para o tratamento primário ou adjuvante das encefalopatias epilépticas fármaco-resistentes, considerando seus benefícios e efeitos adversos. Método: Scoping review fundamentada nas diretrizes do Joanna Briggs Institute. A busca sistemática foi conduzida nos bancos de dados Medline e CINAHL. Resultados: Foram incluídos 12 estudos relevantes que utilizaram o CBD enquanto terapia principal ou tratamento adjuvante das formas refratárias de epilepsia infantil. Considerações Finais: As evidências cumulativas sugerem a segurança e eficácia do uso clínico do canabidiol como terapia para encefalopatia epiléptica refratária pediátrica, proporcionando redução na frequência das crises convulsivas e aumento na resposta ao tratamento convencional.
Downloads
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
1. Beghi E, Giussani G. Aging and the Epidemiology of Epilepsy. Neuroepidemiology. 2018;51(3-4):216-223.
2. Mammas IN, Spandidos DA. The challenge of paediatric epilepsy nursing: An interview with Mrs. Jenny O’Brien, paediatric epilepsy nursing specialist at the Wirral University Teaching Hospital, UK. Exp Ther Med. 2020;20(6):295.
3. Aaberg KM, Gunnes N, Bakken IJ, Lund Søraas C, Berntsen A, Magnus P, et al. Incidence and Prevalence of Childhood Epilepsy: A Nationwide Cohort Study. Pediatrics. 2017;139(5):e20163908.
4. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-82.
5. Chen B, Choi H, Hirsch LJ, Katz A, Legge A, Buchsbaum R, et al. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2017;76:24-31.
6. Sheng J, Liu S, Qin H, Li B, Zhang X. Drug-Resistant Epilepsy and Surgery. Curr Neuropharmacol. 2018;16(1):17-28.
7. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51(6):1069-77.
8. Xue-Ping W, Hai-Jiao W, Li-Na Z, Xu D, Ling L. Risk factors for drug-resistant epilepsy. A systematic review and meta-analysis. Medicine (Baltimore). 2019;98(30):e16402.
9. Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, et al. GWPCARE2 Study Group. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial. JAMA Neurol. 2020;77(5):613-621.
10. Gutiérrez MZ, Nasser E, Castellanos N, Romero K, Lobo F, Paz K, et al. Características clínicas y sociodemográficas de pacientes con epilepsia en un hospital pediátrico en Honduras. Rev Méd Hondur, 2022;90(1):1-94.
11. Ngampoopun M, Nabangchang C, Suwanpakdee P. Survey of local cannabidiol use in parents of children with epilepsy in Thailand: the prevalence, perceptions, and knowledge. J Cannabis Res. 2022;4(1):43.
12. Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 2016;33(12):1357-1392.
13. Gaston TE, Friedman D. Pharmacology of cannabinoids in the treatment of epilepsy. Epilepsy Behav. 2017;70(Pt B):313-318.
14. Abu-Sawwa R, Scutt B, Park Y. Emerging Use of Epidiolex (Cannabidiol) in Epilepsy. J Pediatr Pharmacol Ther. 2020;25(6):485 499.
15. Schlag AK, Zafar R, Nutt D. Medical cannabis and epilepsy in the UK - A qualitative analysis of the carers’ perspective: “We’re asking for quality of life for our children”. Drug Science, Policy and Law. 2021;7:20503245211034930.
16. von Wrede R, Helmstaedter C, Surges R. Cannabidiol in the Treatment of Epilepsy. Clin Drug Investig. 2021;41(3):211-220.
17. NICE (2019) NICE Guideline [NG 144]. Cannabis-based medicinal products. Published November 11th 2019. Availale from: https:// www.nice.org.uk/guidance/ng144 (accessed 13 August 2022).
18. Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil, H. Chapter 11: Scoping Reviews (2020 version). In: Aromataris E, Munn Z (Editors). JBI Manual for Evidence Synthesis, JBI, 2020. Available from: https://synthesismanual.jbi.global
19. Fineout-Overholt E, Melnyk BM, Stillwell SB, Williamson KM. Evidence-based practice, step by step: Critical appraisal of the evidence: part III. Am. J. Nurs. 2010;110(11):43-51.
20. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2022;359:114238.
21. Zafar R, Schlag A, Phillips L, Nutt DJ. Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients. BMJ Paediatr Open. 2021;5(1):e001234.
22. Herlopian A, Hess EJ, Barnett J, Geffrey AL, Pollack SF, Skirvin L, Bruno P, Sourbron J, Thiele EA. Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Epilepsy Behav. 2020;106:106988.
23. Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E. Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: Systematic review and meta-analysis. Epilepsy Behav. 2020;102:106635.
24. Wheless JW, Dlugos D, Miller I, Oh DA, Parikh N, Phillips S, et al; INS011-14-029 Study Investigators. Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy. CNS Drugs. 2019;33(6):593-604.
25. Mitelpunkt A, Kramer U, Hausman Kedem M, Zilbershot Fink E, Orbach R, Chernuha V, et al. The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single center study. Epilepsy Behav. 2019;98(Pt A):233-237.
26. Knupp KG, Rice JD, Helmkamp LJ, Galinkin J, Sempio C, Jost K, Chapman KE. Prospective evaluation of oral cannabis extracts in children with epilepsy. Seizure. 2019;72:23-27. Pane C, Saccà F. The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series. Neurol Sci. 2020;41(3):695-6.
28. Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, et al. Cannabis-based products for pediatric epilepsy: An updated systematic review. Seizure. 2020;75:18-22.
29. Chen KA, Farrar M, Cardamone M, Gill D, Smith R, Cowell CT, et al. Cannabidiol for treating drug-resistant epilepsy in children: the New South Wales experience. Med J Aust. 2018;209(5):217-221.
30. Ali S, Scheffer IE, Sadleir LG. Efficacy of cannabinoids in paediatric epilepsy. Dev Med Child Neurol. 2019;61(1):13-18.
31. Reddy DS. The Utility of Cannabidiol in the Treatment of Refractory Epilepsy. Clin Pharmacol Ther. 2017;101(2):182-184.
32. Orozco-Hernández JP, Quintero-Moreno JF, Marín-Medina DS, Castaño-Montoya JP, Hernández-Coral P, Pineda M, et al. Clinical and sociodemographic profile of epilepsy in adults from a reference center in Colombia. Neurologia (Engl Ed). 2019;34(7):437-444.
33. Caraballo R, Reyes G, Demirdjian G, Huaman M, Gutierrez R. Long-term use of cannabidiol-enriched medical cannabis in a prospective cohort of children with drug-resistant developmental and epileptic encephalopathy. Seizure. 2022;95:56-63.
34. Raucci U, Pietrafusa N, Paolino MC, Di Nardo G, Villa MP, Pavone P, et al. Cannabidiol Treatment for Refractory Epilepsies in Pediatrics. Front Pharmacol. 2020;11:586110.
35. Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, et al. Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis. Drugs. 2018;78(17):1791-1804.
36. Golub V, Reddy DS. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders. Adv Exp Med Biol. 2021;1264:93-110.
37. Treves N, Mor N, Allegaert K, Bassalov H, Berkovitch M, Stolar OE, et al. Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep. 2021;11(1):23462.
38. Silva GD, Del Guerra FB, de Oliveira Lelis M, Pinto LF. Cannabidiol in the Treatment of Epilepsy: A Focused Review of Evidence and Gaps. Front Neurol. 2020;11:531939.
39. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Curr Neuropharmacol. 2019;17(10):974-989.
40. Patel S, Grinspoon R, Fleming B, Skirvin LA, Wade C, Wolper E, et al. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. Epilepsia. 2021;62(7):1594-1603.
41. Gaston TE, Ampah SB, Martina Bebin E, Grayson LP, Cutter GR, Hernando K, et al; UAB CBD Program. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy Behav. 2021;117:107862.
42. Caraballo R, Demirdjian G, Reyes G, Huaman M, Gutierrez R. Effectiveness of cannabidiol in a prospective cohort of children with drug-resistant epileptic encephalopathy in Argentina. Seizure. 2020;80:75-80.
43. Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270–278.
44. Lattanzi S, Trinka E, Striano P, Rocchi C, Salvemini S, Silvestrini M, et al. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome. CNS Drugs. 2021;35(3):265-281.
45. Moreira GA, Moraes Nero R, Ribeiro RG, Crippa ACS. Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature. Rev Paul Pediatr. 2022;41:e2021197. 46. Patel AD, Mazurkiewicz-Bełdzińska M, Chin RF, Gil-Nagel A, Gunning B, Halford JJ, et al. Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: Results of a long-term open-label extension trial. Epilepsia. 2021;62(9):2228-2239.
47. Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45(11):1799-1806.
48. Verducci C, Hussain F, Donner E, Moseley BD, Buchhalter J, Hesdorffer D, et al. SUDEP in the North American SUDEP Registry: The full spectrum of epilepsies. Neurology. 2019;93(3):e227-e236.
49. Malaca S, Busardò FP, Nittari G, Sirignano A, Ricci G. Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights. Curr Pharm Des. 2022;28(32):2603-2617.
50. Pizzo F, Collotta AD, Di Nora A, Costanza G, Ruggieri M, Falsaperla R. Ketogenic diet in pediatric seizures: a randomized controlled trial review and meta-analysis. Expert Rev Neurother. 2022;22(2):169-177.
51. Armeno ML, Kossoff EH. Let food be thy medicine. The interaction between ketogenic diet therapy and anti-seizure medications: A systematic review. Epileptic Disord. 2023;25(1):18-27.
52. Xie H, Ma J, Ji T, Liu Q, Cai L, Wu Y. Vagus nerve stimulation in children with drug-resistant epilepsy of monogenic etiology. Front. Neurol. 2022;13:951850.
53. Batson S, Shankar R, Conry J, Boggs J, Radtke R, Mitchell S et al. Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis. J Neurol. 2022;269:2874 2891.
54. Ji T, Yang Z, Liu Q, Liao J, Yin F, Chen Y et al. Vagus nerve stimulation for pediatric patients with intractable epilepsy between 3 and 6 years of age: study protocol for a double-blind, randomized control trial. Trials. 2019;20(1):44.
55. Geng J, Dong J, Li Y, Ni H, Jiang K, Shi LL, Wang G. Intravenous immunoglobulins for epilepsy. Cochrane Database Syst Rev. 2017;7(7):CD008557.